BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 29209721)

  • 1. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.
    Bridoux F; Carron PL; Pegourie B; Alamartine E; Augeul-Meunier K; Karras A; Joly B; Peraldi MN; Arnulf B; Vigneau C; Lamy T; Wynckel A; Kolb B; Royer B; Rabot N; Benboubker L; Combe C; Jaccard A; Moulin B; Knebelmann B; Chevret S; Fermand JP;
    JAMA; 2017 Dec; 318(21):2099-2110. PubMed ID: 29209721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.
    Hutchison CA; Cockwell P; Moroz V; Bradwell AR; Fifer L; Gillmore JD; Jesky MD; Storr M; Wessels J; Winearls CG; Weisel K; Heyne N; Cook M
    Lancet Haematol; 2019 Apr; 6(4):e217-e228. PubMed ID: 30872075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
    Sens F; Chaintreuil D; Jolivot A; Guebre-Egziabher F; Robinson P; Karlin L; Bridoux F; Juillard L
    Am J Nephrol; 2017; 46(5):355-363. PubMed ID: 29017155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study.
    Peters NO; Laurain E; Cridlig J; Hulin C; Cao-Huu T; Frimat L
    Hemodial Int; 2011 Oct; 15(4):538-45. PubMed ID: 22111823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience of using hemodialysis with medium cut-off dialyzer in cast nephropathy.
    Cazorla López JM; García García-Doncel A; Naranjo Muñoz J; Villanego Fernández F; Vigara Sánchez LA; Ceballos Guerrero M
    Nefrologia (Engl Ed); 2020; 40(3):367-369. PubMed ID: 32007298
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.
    Bridoux F; Arnulf B; Karlin L; Blin N; Rabot N; Macro M; Audard V; Belhadj K; Pegourie B; Gobert P; Cornec Le Gall E; Joly B; Karras A; Jaccard A; Augeul-Meunier K; Manier S; Royer B; Caillot D; Tiab M; Delbes S; Suarez F; Vigneau C; Caillard S; Arakelyan-Laboure N; Roos-Weil D; Chevret S; Fermand JP;
    J Clin Oncol; 2020 Aug; 38(23):2647-2657. PubMed ID: 32574117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.
    Finkel KW; Cohen EP; Shirali A; Abudayyeh A;
    Clin J Am Soc Nephrol; 2016 Dec; 11(12):2273-2279. PubMed ID: 27526708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
    Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
    Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis.
    Krieter DH; Devine E; Wanner C; Storr M; Krause B; Lemke HD
    Artif Organs; 2014 Oct; 38(10):888-93. PubMed ID: 24392952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of acute kidney injury in symptomatic multiple myeloma.
    Bridoux F; Leung N; Belmouaz M; Royal V; Ronco P; Nasr SH; Fermand JP;
    Kidney Int; 2021 Mar; 99(3):570-580. PubMed ID: 33440212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of kidney function following delayed use of Theralite™ dialyzer in a patient with myeloma cast nephropathy.
    Dahal K; Shastri S; Narayanasami U; Bijol V; Rider K; Strom JA; Jaber BL
    Clin Nephrol; 2013 Apr; 79(4):318-22. PubMed ID: 22541683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy.
    Rousseau-Gagnon M; Agharazii M; De Serres SA; Desmeules S
    PLoS One; 2015; 10(10):e0140463. PubMed ID: 26466100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial.
    Bridoux F; Fermand JP
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):333-41. PubMed ID: 22920644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.
    Hutchison CA; Bradwell AR; Cook M; Basnayake K; Basu S; Harding S; Hattersley J; Evans ND; Chappel MJ; Sampson P; Foggensteiner L; Adu D; Cockwell P
    Clin J Am Soc Nephrol; 2009 Apr; 4(4):745-54. PubMed ID: 19339414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy.
    Yamaguchi W; Yui N; Nagao T; Oshikawa G; Negi M; Iimori S; Okado T; Rai T; Uchida S
    Intern Med; 2016; 55(3):263-8. PubMed ID: 26831021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.
    Yadav P; Hutchison CA; Basnayake K; Stringer S; Jesky M; Fifer L; Snell K; Pinney J; Drayson MT; Cook M; Cockwell P
    Eur J Haematol; 2016 Jun; 96(6):610-7. PubMed ID: 26248588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury.
    Steiner N; Abdel Hamid A; Kronbichler A; Neuwirt H; Myslivecek M; Kollar M; Lachmanova J; Rysava R; Hruskova Z; Spicka I; Willenbacher W; Nachbaur D; Wolf D; Tesar V; Gunsilius E
    J Nephrol; 2021 Aug; 34(4):1263-1270. PubMed ID: 33382447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.